Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales - A report from the Children's Oncology Group

Journal of Clinical Oncology

Volumn 32, Issue 6, 2014, Pages 527-534

  Landier, Wendy ^a   Knight, Kristin ^c   Wong, F Lennie ^a   Lee, Jin ^a   Thomas, Ola ^a   Kim, Heeyoung ^a   Kreissman, Susan G ^d   Schmidt, Mary Lou ^e   Chen, Lu ^b   London, Wendy B ^f   Gurney, James G ^g   Bhatia, Smita ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF MEMPHIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

AMERICAN SPEECH LANGUAGE HEARING ASSOCIATION SCALE; ARTICLE; BROCK SCALE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHANG SCALE; CHILD; CHILDHOOD CANCER; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS VERSION 3; DISEASE SEVERITY; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; HEARING AID; HEARING IMPAIRMENT; HEARING TEST; HIGH GRADE NEUROBLASTOMA; HOSPITALIZATION; HOSPITALIZED CHILD; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; OTOTOXICITY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; ADOLESCENT; ADULT; CANCER GRADING; CHEMICALLY INDUCED DISORDER; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; MALE; NEOPLASM GRADING; NEUROBLASTOMA; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84898549438     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2038     Document Type: Article

References (62)

1. Brodeur GM, Hogarty MD, Mosse YP, et al: Neuroblastoma, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Wolters Kluwer-Lippincott Williams and Wilkins, 2011, pp 886-922
2. Cheung NV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
3. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999 (Pubitemid 29480654)
4. Berthold F, Boos J, Burdach S, et al: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 6:649-658, 2005 (Pubitemid 41222755)
5. Yu AL, Gilman AL, Ozkaynak MF, et al: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010
6. Valteau-Couanet D, Michon J, Boneu A, et al: Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 23:532-540, 2005 (Pubitemid 46224230)
7. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007 (Pubitemid 46935947)
8. Laverdière C, Cheung NK, Kushner BH, et al: Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45:324-332, 2005 (Pubitemid 41077167)
9. Barr RD, Chalmers D, De Pauw S, et al: Health-related quality of life in survivors of Wilms' tumor and advanced neuroblastoma: A cross-sectional study. J Clin Oncol 18:3280-3287, 2000
10. Hobbie WL, Moshang T, Carlson CA, et al: Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 51:679-683, 2008
11. McHaney VA, Thibadoux G, Hayes FA, et al: Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 102:314-317, 1983 (Pubitemid 13194726)
12. Schell MJ, McHaney VA, Green AA, et al: Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754-760, 1989 (Pubitemid 19145597)
13. Heck JE, Ritz B, Hung RJ, et al: The epidemiology of neuroblastoma: A review. Paediatr Perinat Epidemiol 23:125-143, 2009
14. Stelmachowicz PG, Pittman AL, Hoover BM, et al: The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 130:556-562, 2004 (Pubitemid 38609664)
15. Wake M, Hughes EK, Poulakis Z, et al: Outcomes of children with mild-profound congenital hearing loss at 7 to 8 years: A population study. Ear Hear 25:1-8, 2004 (Pubitemid 38182600)
16. Bess FH, Dodd-Murphy J, Parker RA: Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear 19:339-354, 1998 (Pubitemid 28465218)
17. Davis JM, Elfenbein J, Schum R, et al: Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 51:53-62, 1986 (Pubitemid 16165644)
18. Li Y, Womer RB, Silber JH: Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 40:2445-2451, 2004 (Pubitemid 39424959)
19. Blakley BW, Myers SF: Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg 109:385-391, 1993 (Pubitemid 23318944)
20. Brock PR, Bellman SC, Yeomans EC, et al: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991
21. Ilveskoski I, Saarinen UM, Wiklund T, et al: Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med Pediatr Oncol 27:26-31, 1996
22. Montaguti M, Brandolini C, Ferri GG, et al: Cisplatin and carboplatin-induced ototoxicity in children: Clinical aspects and perspectives for prevention [in Italian]. Acta Otorhinolaryngol Ital 22:14-18, 2002
23. Skinner R, Pearson AD, Amineddine HA, et al: Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 61:927-931, 1990 (Pubitemid 20197008)
24. Kushner BH, Budnick A, Kramer K, et al: Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417-422, 2006 (Pubitemid 44036572)
25. Knight KR, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596, 2005 (Pubitemid 46211500)
26. Stohr W, Langer T, Kremers A, et al: Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system. Cancer Invest 23:201-207, 2005 (Pubitemid 40770737)
27. Lewis MJ, DuBois SG, Fligor B, et al: Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387-391, 2009
28. Gupta AA, Capra M, Papaioannou V, et al: Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors. J Pediatr Hematol Oncol 28:91-94, 2006
29. Bertolini P, Lassalle M, Mercier G, et al: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649-655, 2004 (Pubitemid 39350398)
30. Bates DE, Beaumont SJ, Baylis BW: Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 36:446-451, 2002 (Pubitemid 34205320)
31. Ross CJ, Katzov-Eckert H, Dubé MP, et al: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41:1345-1349, 2009
32. Riedemann L, Lanvers C, Deuster D, et al: Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8:23-28, 2008
33. Brock PR, Knight KR, Freyer DR, et al: Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30:2408-2417, 2012
34. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
35. Brock PR, Yeomans EC, Bellman SC, et al: Cisplatin therapy in infants: Short and long-term morbidity. Br J Cancer Suppl 18:S36-S40, 1992
36. Pritchard J, Brown J, Shafford E, et al: Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - Results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 18:3819-3828, 2000
37. Parsons SK, Neault MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669-674, 1998 (Pubitemid 28486365)
38. American Speech-Language-Hearing Association: Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36:11-19, 1994 (suppl 12)
39. Chang KW, Chinosornvatana N: Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788-1795, 2010
40. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-40
41. Neuwelt EA, Brock P: Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630-1632, 2010
42. Katzenstein HM, Chang KW, Krailo M, et al: Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 115:5828-5835, 2009
43. Kreissman SG, Seeger RC, Matthay KK, et al: Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomised phase 3 trial. Lancet Oncol 14:999-1008, 2013
44. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37-46, 1960
45. Zhang H, Xia Y, Chen R, et al: On modeling longitudinal binomial responses: Implications from two dueling paradigms. J Appl Stat 38:2373-2390, 2011
46. Breslow NE, Clayton DG: Approximate inference in generalized linear mixed models. J Am Stat Assoc 88:9-25, 1993
47. Siegel S: Nonparametric Statistics for the Behavioral Sciences. New York, NY, McGraw-Hill, 1956
48. Cox DR: Analysis of Binary Data. London, United Kingdom, Chapman and Hall, 1969
49. Womer RB, Pritchard J, Barratt TM: Renal toxicity of cisplatin in children. J Pediatr 106:659-663, 1985 (Pubitemid 15080566)
50. Schacht J, Talaska AE, Rybak LP: Cisplatin and aminoglycoside antibiotics: Hearing loss and its prevention. Anat Rec (Hoboken) 295:1837-1850, 2012
51. Punnett A, Bliss B, Dupuis LL, et al: Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study. Pediatr Blood Cancer 42:598-603, 2004 (Pubitemid 38669747)
52. Maris JM: Recent advances in neuroblastoma. N Engl J Med 362:2202-2211, 2010
53. Castleberry RP, Cantor AB, Green AA, et al: Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 12:1616-1620, 1994 (Pubitemid 24244997)
54. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607-2613, 1994 (Pubitemid 24379646)
55. Ladenstein RL, Poetschger U, Luksch R, et al: Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. J Clin Oncol 29:5s, 2011 (suppl; abstr 2)
56. Ladenstein R, Valteau-Couanet D, Brock P, et al: Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study. J Clin Oncol 28:3516-3524, 2010
57. Ding D, Allman BL, Salvi R: Review: Ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken) 295:1851-1867, 2012
58. Horwitz AR, Dubno JR, Ahlstrom JB: Recognition of low-pass-filtered consonants in noise with normal and impaired high-frequency hearing. J Acoust Soc Am 111:409-416, 2002 (Pubitemid 34093335)
59. Berg AL, Spitzer JB, Garvin JH Jr: Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 109:1806-1814, 1999 (Pubitemid 29533925)
60. Grewal S, Merchant T, Reymond R, et al: Auditory late effects of childhood cancer therapy: A report from the Children's Oncology Group. Pediatrics 125:e938-e950, 2010
61. Gurney JG, Tersak JM, Ness KK, et al: Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 120:e1229-e1236, 2007 (Pubitemid 350085519)
62. Chang KW: Clinically accurate assessment and grading of ototoxicity. Laryngoscope 121:2649-2657, 2011